Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & EnergyRevcovi (elapegademase-lvlr) is a new enzyme replacement therapy indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.
In the last several years, global market of Elapegademase-lvlr developed rapidly, with an average growth rate of 9.14% during 2014 to 2018. In 2018, global revenue of Elapegademase-lvlr is nearly 11 M USD; the actual sales are about 1934 Unit.
This report focuses on Elapegademase-lvlr volume and value at global level, regional level and company level. From a global perspective, this report represents overall Elapegademase-lvlr market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, and Japan.
At company level, this report focuses on the sales, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
Leadiant Biosciences
Orchard Therapeutics
Teijin Pharma
Segment by Regions
North America
Europe
Japan
Rest of World
Segment by Type
Revcovi
Strimvelis
Adagen
Segment by Application
Pediatric
Adult
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
